Preclinical studies have shown that gefitinib increased the response to carboplatin and docetaxel [73]; doxazosin reduced EGFR expression [74]; epertinib inhibited EGFR and HER2 [75]; almonertinib inhibited the multi-resistance of cancer cells [76]. This evidence concerns the gene EGFR and cancer.